Carefirst. +.V Family of health care plans

Similar documents
STEP THERAPY WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA. AVINZA (morphine extended-release capsules)

Drug Name (specify drug) Quantity Frequency Strength

QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA

Drug Name (specify drug) Quantity Frequency Strength

Opioid Management Program October 2018

Long-Acting Opioid Analgesics

Long-Acting Opioid Analgesics

Opioid Management Program May 2018

Pequot Health Care Opioid Analgesic Quantity Program*

20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days

Generic Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE

Prior Authorization for Opioid Products Indicated for Pain Management

Long-Acting Opioid. Policy Number: Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018

Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017)

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Prior Authorization Guideline

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

APPROVED PA CRITERIA. Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION

EXTENDED RELEASE OPIOID DRUGS

Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

: Opioid Quantity Limits

Opioid Analgesics. Recommended starting dose for opioid-naïve patients

Pharmacy Medical Necessity Guidelines: Opioid Analgesics

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary October 1, 2018 Updates. Formulary. Alternatives

Medication Policy Manual. Date of Origin: January 1, Topic: Extended-release (ER) Opioid Medication Products for Pain

See Important Reminder at the end of this policy for important regulatory and legal information.

MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111

Cigna Drug and Biologic Coverage Policy

Medication Policy Manual. Topic: Extended-release (ER) Opioid Medication Products for Pain. Date of Origin: January 1, 2018

DURATION LIMIT WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA IMMEDIATE-RELEASE OPIOID ANALGESICS (BRAND AND GENERIC)*

Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics

Cigna Drug and Biologic Coverage Policy

Addressing Drug Diversion

Xyrem (Sodium Oxybate)

15 mg morphine 10 mg hydrocodone

Extended Release Opioid Drugs

Opioid Analgesic Treatment Worksheet

Prescription Drugs with Dispensing Limits or Prior Authorization Requirements

Extended Release Opioid Drugs

How To Green My Pharmacy. Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist

Session VI. Presenter Disclosure Information. Learning Objectives for Session VI. Prescribing Information. Prescribers Must Be Knowledgeable

Opioid Prescribing Guidelines for Patients in the Emergency Department

Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans

Drug Formulary Commission

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids

ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care

Opioid Analgesic Treatment Worksheet

Extended Release Opioid Drugs

Opiate/Benzodiazepine/Muscle Relaxant Combinations

Disposal of Unused Medicines: What You Should Know

1/29/2013. Schedule II Controlled Substances: Basics and Beyond. Controlled Substances. Controlled Substances, Schedule I

Pharmacy Management Drug Policy

Blueprint for Prescriber Continuing Education Program

Disposal of Unused Medicines: What You Should Know

2. Is this request for a preferred medication? Y N

Immediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy

Morphine Sulfate Hydromorphone Oxymorphone

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization

Prior Authorization Opioid Overutilization 2017

New Hampshire Healthy Families CLINICAL POLICY

Conversion chart from fentanyl to opana er

3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)?

Session VI. SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education. Presenter Disclosure Information. Presenting Faculty

Diabetes Fortamet (metformin ER), Glumetza (metformin ER) generic of Glucophage XR (metformin ER) preferred

Texas Prior Authorization Program Clinical Edit Criteria

Methadone. Description

Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics

Limitations of use: Subsys may be dispensed only to patients enrolled in the TIRF REMS Access program (1).

DURATION LIMIT CRITERIA ACETAMINOPHEN/ASPIRIN/IBUPROFEN CONTAINING OPIOID ANALGESICS (BRAND AND GENERIC) (acetaminophen and benzhydrocodone)

Collaboration for REMS Education

Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description

Disposal by Flushing of Certain Unused Medicines: What

``Considerations for using opioid drug therapy in workers compensation include patient safety, drug effectiveness and financial impacts

Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics

Duragesic patch. Duragesic patch (fentanyl patch) Description

Drug Use Evaluation: Short Acting Opioids (SAO)

Morphine er to oxycontin conversion

Prescription Drug Abuse: Colorado and Nationwide

Abuse Deterrent Opioid Formulations Claire Saadeh, PharmD, BCOP / August 2017

Equianalgesic Dosing of Opioids for Pain Management

Opioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital

Proposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)

Pharmacological Pain Management, the Evolving Role of Opioids, and Improving Education of Health Care Providers

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)

Effect of Abuse-Deterrent Formulations and IR Opioids on Abuse, Overdose and Death from Rx Opioids

Interprofessional Webinar Series

paindr.com ABUSE DETERRENT FORMULATIONS CURRENT AND PIPELINE Update August, 2017 Table 1: Opioids with Abuse Deterrent Properties

Egalet Corporate Presentation

Nucynta IR/ Nucynta ER (tapentadol immediate-release and extendedrelease)

Demerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)

Opioid Analgesics with Abuse- Deterrent Properties: Current Data and Future Opportunities

Evaluating the Impact of Abuse Deterrent Formulations: Methodological Challenges in Postmarketing Data

Can Chronic Opioid Therapy Be Used Safely and Effectively for the Treatment of Chronic Pain? Charles E. Argoff, MD, CPE

Drug Name (specify drug) Quantity Frequency Strength

Convert hydrocodone to ms contin

Abbreviated Class Update: Long-Acting Opioids (LAOs)

Class Update with New Drug Evaluation: Long Acting Opioids

See Important Reminder at the end of this policy for important regulatory and legal information.

Transcription:

Family of health care plans Prior Authorization Form 1361M Opioids ER MME Limit and Post Limit This fax machine is located in a secure location as required by HPAA regulations. Complete/review information, sign and date. Fax signed forms to CVS/Caremark at 18888360730. Please contact CVS/Caremark at 18002945979 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of 1361M Opioids ER MME Limit and Post Limit. Drug Name (specify drug) Quantity Frequency Strength Route of Administration Expected Length of Therapy Patient nformation Patient Name: Patient D: Patient Group No.: Patient DOB: Patient Phone: Prescribing Physician Physician Name: Physician Phone: Physician Fax: Physician Address: City, State, Zip: Diagnosis: Comments: CD Code: Please circle the appropriate answer for each question. 1. s the requested drug being prescribed for pain associated with cancer, a terminal condition, or pain being managed through hospice or palliative care? [f yes, then no further questions.] 2. s the requested drug being prescribed for pain severe enough to require daily, aroundtheclock, longterm treatment in a patient who has been taking an opioid? 3. Can the patient safely take the requested dose based on their history of opioid use? CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, nc. and Group Hospitalization and Medical Services, nc. CareFirst of Maryland, nc., Group Hospitalization and Medical Services, nc., and CareFirst BlueChoice, nc. are independent licensees of the Blue Cross and Blue Shield

4. Has the patient been evaluated and will the patient be monitored regularly for the development of opioid use disorder? 5. Will the patient's pain be reassessed in the first month after the initial prescription or any dose increase AND every 3 months thereafter to ensure that clinically meaningful improvement in pain and function outweigh risks to patient safety? 6. Which drug is being requested? Please check drug being requested. D D D D D D D D J D D D D D L D l D D [Note: These drugs should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.] Arymo ER (morphine extendedrelease tablets) (if checked, go to 18) Avinza (morphine extendedrelease capsules) (if checked, go to 10) Belbuca (buprenorphine buccal film) (if checked, go to 11) Butrans (buprenorphine transdermal system) (if checked, go to 12) Conzip (tramadol hydrochloride extendedrelease) (if checked, go to 13) Dolophine 5 mg, 10 mg (methadone hydrochloride tablets) (if checked, go to 8) Duragesic (fentanyl transdermal system) (if checked, go to question 14) Embeda (morphine sulfate/naltrexone HCl extendedrelease) (if checked, go to question 15) Exalgo (hydromorphone hydrochloride extendedrelease) (if checked, go to question 16) Hysingla ER (hydrocodone bitartrate extendedrelease tablets) (if checked, go to 7) Kadian (morphine extendedrelease capsules) (if checked, go to question 17) Methadone 10 mg/ml ntensol soln (if checked, go to 8) Methadone 5 mg/5 ml,10 mg/5 ml oral soln, 200 mg/20 ml injection (if checked, go to 8) Methadose 5 mg, 10 mg (methadone hydrochloride tablets) (if checked, go to 8) Morphabond (morphine extendedrelease tablets) (if checked, go to 18) MS Contin (morphine extendedrelease tablets) (if checked, go to 18) CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, nc. and Group Hospitalization and Medical Services, nc. CareFirst of Maryland, nc., Group Hospitalization and Medical Services, nc., and CareFirst BlueChoice, nc. are independent licensees of the Blue Cross and Blue Shield

Nucynta ER (tapentadol extendedrelease) (if checked, go to 19) Opana ER (oxymorphone hydrochloride extendedrelease tablets) (if checked, go to 20) OxyContin (oxycodone hydrochloride extendedrelease tablet) (if checked, go to 21) Targiniq ER (oxycodone HCl/naloxone HCl extendedrelease tablets) (if checked, go to 22) tramadol extendedrelease (if checked, go to 13) Ultram ER (tramadol extendedrelease) (if checked, go to 13) Vantrela ER (hydrocodone bitartrate extendedrelease tablets) (if checked, go to 7) Xtampza ER (oxycodone extendedrelease capsules) (if checked, go to 23) Zohydro ER (hydrocodone bitartrate extendedrelease capsules) (if checked, go to 7) Troxyca ER (oxycodone/naltrexone extendedrelease capsules) (if checked, go to 24) 7. Does the patient require use of MORE than any of the following: A) 60 units/month of Hysingla ER 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, 100 mg OR Zohydro ER 50 mg OR Vantrela ER 60 mg, 90 mg, B) 30 units/month of Hysingla ER 120 mg, C) 90 units/month of Zohydro ER 10 mg, 15 mg, 20 mg, 30 mg, 40 mg OR Vantrela ER 15 mg, 30 mg, 45 mg? 8. s the methadone product being prescribed for detoxification treatment or as part of a maintenance treatment plan for opioid/substance abuse or addiction? 9. Does the patient require use of MORE than any of the following: A) 120 tablets/month of Dolophine or Methadose, B) 600 ml/month of Methadone oral solution (5 mg/5 ml or 10 mg/5 ml), C) 40 ml (2 multidose vials) of Methadone 200 mg/20 ml injection, D) 120 ml/month of Methadone ntensol (10 mg/ml) solution? 10. Does the patient require use of MORE than 60 capsules/month of Avinza 30 mg, 45 mg, 60 mg, 75 mg, 90 mg OR 30 capsules/month of Avinza 120 mg? 11. Does the patient require use of MORE than 90 films/month of Belbuca 75 mcg, 150 mcg, 300 mcg, 450 mcg OR MORE than 60 films/month of Belbuca 600 mcg, 750 mcg, 900 mcg? D D D D D D D D D D _ l CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, nc. and Group Hospitalization and Medical Services, nc. CareFirst of Maryland, nc., Group Hospitalization and Medical Services, nc., and CareFirst BlueChoice, nc. are independent licensees of the Blue Cross and Blue Shield

12. Does the patient require use of MORE than 8 patches/month of Butrans 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr OR MORE than 4 patches/month of Butrans 15 mcg/hr, 20 mcg/hr? 13. Does the patient require use of MORE than 60 units/month of Conzip 100 mg, tramadol ER 100 mg, 150 mg, or Ultram ER 100 mg, OR 30 units/month of Conzip 200 mg, 300 mg, or tramadol ER 200 mg, 300 mg, or Ultram ER 200 mg, 300 mg? 14. Does the patient require use of MORE than 20 patches/month of Duragesic 12 mcg, 25 mcg, 37.5 mcg OR MORE than 10 patches/month of Duragesic 50 mcg, 62.5 mcg, 75 mcg, 87.5 mcg, 100 mcg? 15. Does the patient require use of MORE than 90 capsules/month of Embeda 20/0.8 mg, 30/1.2 mg OR MORE than 60 capsules/month of Embeda 50/2 mg, 60/2.4 mg, 80/3.2 mg, 100/4 mg? 16. Does the patient require use of MORE than 60 tablets/month of Exalgo 8 mg, 12 mg, 16 mg OR MORE than 30 tablets/month of Exalgo 32 mg? 17. Does the patient require use of MORE than any of the following: A) 90 capsules/month of Kadian 10 mg, 20 mg, 30 mg, 40 mg, B) 60 capsules/month of Kadian 50 mg, 60 mg, 70 mg, 80 mg, 100 mg, C) 30 capsules/month of Kadian 130 mg, 150 mg, 200 mg? 18. Does the patient require use of MORE than any of the following: A) 90 tablets/month of Arymo ER 60 mg or MorphaBond 15 mg, 30 mg or MS Contin 60 mg, B) 120 tablets/month of Arymo ER 15 mg, 30 mg or MS Contin 15 mg, 30 mg, C) 60 tablets/month of MorphaBond 60 mg, 100 mg or MS Contin 100 mg, 200 mg? 19. Does the patient require use of MORE than 90 tablets/month of Nucynta ER 50 mg, 100 mg, 150 mg OR MORE than 60 tablets/month of Nucynta ER 200 mg, 250 mg? CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, nc. and Group Hospitalization and Medical Services, nc. CareFirst of Maryland, nc., Group Hospitalization and Medical Services, nc., and CareFirst BlueChoice, nc. are independent licensees of the Blue Cross and Blue Shield

20. Does the patient require use of MORE than 90 tablets/month of Opana ER 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, OR 60 tablets/month of Opana ER, 30 mg, 40 mg? 21. Does the patient require use of MORE than 90 tablets/month of OxyContin 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, OR 60 tablets/month of OxyContin 60 mg, 80 mg? 22. Does the patient require use of MORE than 90 tablets/month of Targiniq ER 10 mg/5 mg, 20 mg/10 mg OR 60 tablets/month of Targiniq ER 40 mg/20 mg? 23. Does the patient require use of MORE than 90 capsules/month of Xtampza ER? 24. Does the patient require use of MORE than 90 capsules/month of Troxyca ER 10 mg/1.2 mg, 20 mg/2.4 mg, 30 mg/3.6 mg, 40 mg/4.8 mg OR 60 capsules/month of Troxyca ER 60 mg/7.2 mg, 80 mg/9.6 mg? affirm that the information given on this form is true and accurate as of this date. Prescriber (Or Authorized) Signature and Date CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, nc. and Group Hospitalization and Medical Services, nc. CareFirst of Maryland, nc., Group Hospitalization and Medical Services, nc., and CareFirst BlueChoice, nc. are independent licensees of the Blue Cross and Blue Shield